Positron emission tomography using radiolabeled prostate specific membrane antigen targeting PET-imaging agents such as 68Ga-PSMA-11, 18F-PSMA-1007, and 18F-DCFPyl have been increasingly used over the past decade for imaging and directing prostate carcinoma treatment [8,9]. Here, FOLH1 is linked to prostate carcinoma.